Company / EPS (Diluted)
Amphstar Pharmaceuticals, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$2.60
FY2025
5-year range
$0.03 / $2.60
FY2021-FY2025
Trend
+49.4%
vs FY2024
Sector context
#19 of 204
Health Care
What the data says
Among 204 Health Care companies, Amphstar Pharmaceuticals, Inc. is in the top 9% for eps (diluted). EPS (Diluted) has increased for 3 consecutive years, from $0.03 in FY2022 to $2.60 in FY2025.
Based on SEC 10-K filings.
2.60 in FY2025 with a 3-year CAGR of +342.5%. Top quartile in the Health Care sector.
Improved from $1.25 to $2.60 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +342.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 204This company $2.60 Sector average -$0.89
▼
+393.4% above sector average
Key checks
Key Insights
- Amphstar Pharmaceuticals, Inc.'s eps (diluted) has grown for 3 consecutive years.
- In FY2025, eps (diluted) increased 49.4% year-over-year.
- Ranks #19 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.60 | +49.4% |
| FY2024 | $1.74 | +39.2% |
| FY2023 | $1.25 | +4066.7% |
| FY2022 | $0.03 | -96.9% |
| FY2021 | $0.98 | +916.7% |
| FY2020 | -$0.12 | -250.0% |
| FY2019 | $0.08 | -61.9% |
| FY2018 | $0.21 | +450.0% |
| FY2017 | -$0.06 | +76.0% |
| FY2016 | -$0.25 | -180.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026